US Stock MarketDetailed Quotes
SNSE Sensei Biotherapeutics
- 1.260
- +0.240+23.54%
Close May 1 16:00 ET
31.60MMarket Cap-1032P/E (TTM)
1.290High0.971Low604.21KVolume0.980Open1.020Pre Close717.97KTurnover3.68%Turnover RatioLossP/E (Static)25.08MShares1.67052wk High0.49P/B20.69MFloat Cap0.51052wk Low--Dividend TTM16.42MShs Float26.500Historical High--Div YieldTTM31.26%Amplitude0.510Historical Low1.188Avg Price1Lot Size
Sensei Biotherapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 17.94%-32.02M | 35.63%-6.16M | 31.49%-4.66M | 20.47%-9.46M | -9.17%-11.74M | -28.97%-39.03M | -21.68%-9.57M | -21.98%-6.8M | -96.78%-11.9M | 0.16%-10.75M |
| Net income from continuing operations | 29.82%-34.1M | 39.39%-7.41M | 46.90%-7.12M | 10.91%-9.39M | 17.96%-10.18M | -32.05%-48.59M | -30.60%-12.23M | -38.52%-13.42M | -7.82%-10.54M | -55.61%-12.41M |
| Operating gains losses | 1,106.67%302K | --0 | 140.00%6K | --200K | 740.00%96K | 94.97%-30K | --0 | 97.35%-15K | --0 | ---15K |
| Depreciation and amortization | 0.30%1.35M | -6.27%329K | -2.92%332K | 3.75%332K | 7.19%358K | 96.64%1.35M | 6.69%351K | 151.47%342K | 162.30%320K | 240.82%334K |
| Other non cash items | 13.65%1.36M | 20.52%370K | 6.00%318K | 19.26%353K | 8.59%316K | 1,994.74%1.19M | 501.96%307K | 29,900.00%300K | 14,700.00%296K | 9,600.00%291K |
| Change In working capital | -529.56%-4.33M | -161.07%-400K | -78.46%979K | 51.35%-1.72M | -378.86%-3.19M | 761.54%1.01M | 604.30%655K | 75.62%4.55M | -309.70%-3.53M | 84.29%-667K |
| -Change in prepaid assets | 82.99%-99K | -26.42%337K | -75.05%473K | 172.23%671K | 21.28%-1.58M | -170.29%-582K | -29.75%458K | -1.04%1.9M | -468.65%-929K | -0.75%-2.01M |
| -Change in payables and accrued expense | -215.57%-2.33M | -324.46%-781K | -78.92%471K | 15.47%-2.26M | -90.85%242K | 241.44%2.02M | 81.93%-184K | 201.89%2.23M | -465.71%-2.68M | 240.64%2.64M |
| -Change in other current assets | 340.00%22K | 73.08%-7K | 2.33%-42K | 178.22%79K | -104.57%-8K | 101.53%5K | 69.41%-26K | 86.89%-43K | -380.56%-101K | 250.00%175K |
| -Change in other current liabilities | -11.48%-1.27M | -24.91%-366K | -5.24%-301K | -21.01%-334K | 5.24%-271K | -656.59%-1.14M | -172.17%-293K | -10.42%-286K | -4,700.00%-276K | -650.00%-286K |
| -Change in other working capital | -191.68%-650K | -40.43%417K | -49.19%378K | -71.18%132K | -32.19%-1.58M | -15.29%709K | 407.25%700K | 43.35%744K | -30.08%458K | -151.16%-1.19M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 17.94%-32.02M | 35.63%-6.16M | 31.49%-4.66M | 20.47%-9.46M | -9.17%-11.74M | -28.97%-39.03M | -21.68%-9.57M | -21.98%-6.8M | -96.78%-11.9M | 0.16%-10.75M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -23.10%38.41M | -48.50%8.26M | -2.41%8.31M | 47.97%19.53M | -81.04%2.31M | 134.90%49.95M | 185.87%16.04M | 1,867.01%8.52M | 108.93%13.2M | 2,603.70%12.19M |
| Net PPE purchase and sale | 95.42%-14K | --0 | --0 | 346.15%128K | -647.37%-142K | 82.08%-306K | --0 | -235.71%-235K | 91.56%-52K | 96.10%-19K |
| Net investment purchase and sale | -23.54%38.43M | -48.50%8.26M | -5.03%8.31M | 46.42%19.4M | -79.91%2.45M | 135.54%50.26M | 160.99%16.04M | 2,224.27%8.75M | 109.00%13.25M | --12.21M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -23.10%38.41M | -48.50%8.26M | -2.41%8.31M | 47.97%19.53M | -81.04%2.31M | 134.90%49.95M | 185.87%16.04M | 1,867.01%8.52M | 108.93%13.2M | 2,603.70%12.19M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -3,793.03%-11.17M | -247.58%-431K | -1,454.60%-2.53M | -6,577.31%-7.95M | -320.17%-262K | -100.18%-287K | -5.08%-124K | -2,228.57%-163K | -981.82%-119K | -99.93%119K |
| Net issuance payments of debt | -20.99%-761K | -10.73%-196K | -16.56%-190K | -21.15%-189K | -39.85%-186K | -146.67%-629K | 22.03%-177K | -2,228.57%-163K | -1,318.18%-156K | -1,230.00%-133K |
| Net common stock issuance | ---10.38M | ---252K | ---2.34M | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | -85.96%48K | -67.92%17K | --0 | -16.22%31K | --0 | 213.76%342K | -50.93%53K | --0 | --37K | 25,100.00%252K |
| Net other financing activities | ---76K | --0 | --0 | --0 | ---76K | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -3,793.03%-11.17M | -247.58%-431K | -1,454.60%-2.53M | -6,577.31%-7.95M | -320.17%-262K | -100.18%-287K | -5.08%-124K | -2,228.57%-163K | -981.82%-119K | -99.93%119K |
| Net cash flow | ||||||||||
| Beginning cash position | 148.57%17.8M | -0.93%11.34M | 3.30%10.23M | -7.02%8.11M | 148.57%17.8M | -56.86%7.16M | 20.11%11.45M | -36.54%9.9M | -94.85%8.72M | -56.86%7.16M |
| Current changes in cash | -144.98%-4.78M | -73.71%1.67M | -27.98%1.12M | 79.71%2.12M | -720.10%-9.69M | 212.71%10.64M | 367.27%6.35M | 125.57%1.55M | 100.77%1.18M | -98.98%1.56M |
| End cash Position | -26.88%13.01M | -26.88%13.01M | -0.93%11.34M | 3.30%10.23M | -7.02%8.11M | 148.57%17.8M | 148.57%17.8M | 20.11%11.45M | -36.54%9.9M | -94.85%8.72M |
| Free cash flow | 18.16%-32.2M | 35.63%-6.16M | 33.91%-4.66M | 20.58%-9.49M | -10.38%-11.89M | -21.87%-39.35M | -13.94%-9.57M | -18.24%-7.05M | -79.36%-11.95M | 4.31%-10.77M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg